Phase 1 study of fludarabine combined with rituximab followed by Zevalin for patients with relapsed or refractory indolent B cell lymphoma
- Conditions
- Indolent B cell lymphoma
- Registration Number
- JPRN-UMIN000003867
- Lead Sponsor
- Tohoku Hematology Form
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Not provided
(a)History of hematopoietic stem cell transplantation (b)History of whole pelvic or whole abdomen radiation (c)Received G-CSF or erythropoietin or transfusion less than one week before registration (d)Taken an operation less than four weeks before registration (e)History of Zevalin therapy (f)History of the treatment of purin analogs (g)Have active systemic infections (h)Have a serious complication(cardiac dysfunction, hepatic failure, or renal failure) (i)Have a serious digestive organ symptom (j)Have a serious bleeding tendency (k) Positive for HBs antigen, HCV antibody, or HIV antibody. (l)Have an interstitial pneumonia or fibrosis (m)Active cancers (n)Have or history of autoimmune hemolytic anemia (o)Have aglucoma (p) Otherwise judged by investigator to be unsuitable
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Periods from the initiation of Zevalin therapy to the time of bone marrow recovery, neutrophil count is more than 1000/mm3 and pletlet count is more than 50000/mm3.
- Secondary Outcome Measures
Name Time Method